“…[1][2][3] The need for life-long therapy requires the availability of potent ARV regimens that are well-tolerated because virologic failure and drug resistance is unfortunately common among children and adolescents. [4][5][6][7][8] In addition, significant concerns remain regarding toxicities associated with widely used ARVs, including neuropsychiatric toxicities with efavirenz, gastrointestinal toxicities such as diarrhea with multiple protease inhibitors (PIs), weight gain with integrase strand transfer inhibitors (INSTIs), and serum lipid abnormalities associated with multiple ARV classes. Thus, potent treatment regimens that have excellent safety and tolerability profiles and are convenient are still highly desirable.…”